Learn about the growing impact of Multiple Myeloma in the African American community.
TANCIT is a free cancer workshop, at which various cancers are discussed. TANCIT features information on the growing impact of Multiple Myeloma in the African America community.
2018 TANCIT Programs
|Date||Location of Event|
|September 22, 2018||Washington D.C.||Details|
|October 20, 2018||South Haven, MS|
|November 3, 2018||Oakland, CA|
What is TANCIT?
“There’s A New Cancer In Town” is a Minority Community Cancer Workshop, that focuses on Multiple Myeloma. Breakfast and lunch are provided. More information on multiple myeloma is needed in the minority community because African Americans are two to three times more likely to get this cancer than other races This type of cancer is somewhat rare, so myeloma signs and symptoms are often misunderstood and the disease can be misdiagnosed. Education and awareness can change this. Early diagnosis and modern treatments can lead to better outcomes for myeloma patients.
What do you mean by community workshop?
This means the audience will take an interactive role in the educational program and surveys will help them learn and communicate what they have learned. Throughout the workshop, they will have the opportunity to ask questions and gain access to information and resources that are important to raise awareness of multiple myeloma and other cancers.
What will you be doing at the working luncheon?
There will be physicians and patients talking about cancer in general and focusing upon Multiple Myeloma. A panel of Multiple Myeloma patients will present issues they faced in discovery. And, doctors will talk about signs and symptoms and treatment innovations. The audience will participate in helping to suggest how best to reach the African American population, and how to increase awareness of Multiple Myeloma among their own constituencies.
Who is invited and will be attending the Community and Workshop?
The audience will be made up of community leaders, health ministries, churches, cancer survivors and patients (all cancers), caregivers and general public. The medical professionals will include hospital representatives, medical students, research staff and professional caretakers.
Will there be doctors there?
Yes. Hematologists, Oncologists and other medical professionals who work with various diseases such as Breast, Prostate, and Colon cancer, Kidney disease, and Multiple Myeloma will be on hand to answer questions.
I’m a cancer survivor. Will I have a chance to meet others like myself and talk with them and tell my story?
Yes. The workshops are designed to allow for Q&A and discussion time with your table team. Hopefully you’ll continue the conversation at a future health event in which you have personal involvement.
Who are the presenters and sponsors of this event?
The Multiple Myeloma Research Foundation (MMRF), partnering with 50 Hoops’ national “AACT I, II (African Americans in Clinical Trials) Lecture Series,” are the presenters of TANCIT. Amgen, Bristol-Myers Squibb and Takeda Oncology are the corporate sponsors of TANCIT.
What is Multiple Myeloma?
Multiple myeloma is cancer of the plasma cells, which are a type of blood cell that helps to fight infection in your body. In multiple myeloma, abnormal cancerous plasma cells grow quickly and accumulate in the bone marrow (the soft, spongy tissue at the center of your bones), crowding out the normal blood cells. This makes it hard for your body to fight infection, can cause your bones to become weaker and break, and can make you tired because you don’t have enough normal blood cells left to give you energy. The cancer cells also produce a large amount of an abnormal protein, called M protein, which circulates in your blood and may cause kidney damage. Right now there is no cure for multiple myeloma, but there are many effective treatments available that can help patients live for many years with the disease. The mission of the MMRF is to promote awareness of multiple myeloma and to help develop new medicines that may someday lead to a cure.
Brought to you by: